The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2018.02100
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents

Safety and Risk of Pharmacotherapy
2020English

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research
Cancer ResearchOncology
2018English

Immune Checkpoint Inhibitors and irAEs

Trends in Immunotherapy
2018English

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Frontiers in Immunology
AllergyImmunology
2018English

Review of Cancer Treatment With Immune Checkpoint Inhibitors

Wiener Klinische Wochenschrift
Medicine
2017English

Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges

Immunotherapy
OncologyAllergyImmunology
2016English

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Oncologist
Cancer ResearchMedicineOncology
2019English

Immune Checkpoint Inhibitors in the Treatment of Virus-Associated Cancers

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

Immune Checkpoint Inhibitors in Melanoma: Review and Update

Journal of the Portuguese Society of Dermatology and Venereology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy